technical paper
Peer Reviewed Evaluation of Registered End-Points of Randomized Trials (the PRE-REPORT Study)
keywords:
trial registration
editorial and peer review process
peer review
Objective To test whether providing information from
relevant clinical trial registry entries to peer reviewers
evaluating trial manuscripts decreases discrepancies between
registered and published trial outcomes.1,2
Design This stepped-wedge, cluster-randomized trial studied
clusters comprised of eligible clinical trial manuscripts
submitted to each of 13 high-impact medical journals across a
range of medical specialties between November 1, 2018, and
October 31, 2019.3 All participating journals routinely
published results from clinical trials. Each journal began the
study in the control phase; journals were crossed over into the
intervention phase in random order. Manuscripts submitted
during the study period were included if they presented
results from the primary analysis of a clinical trial and
underwent external peer review. Peer reviewers were not told
that a study was taking place. Preexisting peer review
practices were unchanged during the control phase. Peer
reviewers for intervention-phase manuscripts received a data
sheet describing whether the trial was registered, the initial
registration and enrollment dates, and the registered primary
outcome(s) when enrollment began. Decision editors had
access to the registry data sheets. The primary end point was
the presence of a published primary outcome consistent with
a prospectively defined primary outcome in the study’s trial
registry (ie, registered before enrollment began), as
determined independently by 2 outcome assessors blinded to
each manuscript’s study arm. Linear mixed models were used
to estimate outcome differences between intervention- and
control-condition manuscripts. For the primary end point,
use of a 1-sided test at the 5% level was prespecified, with
corresponding 90% CIs, based on the assumption that the
intervention was unlikely to increase outcome
inconsistencies.
Results The study included 419 submitted manuscripts.
Participating journals published 105 of 243 control-phase
manuscripts (43%) and 68 of 176 intervention-phase
manuscripts (39%) (model-estimated difference between
intervention and control, −10%; 95% CI, −25% to 4%).
Among the 173 accepted manuscripts, published primary
outcomes were consistent with clearly defined, prospectively
registered primary outcomes in 40 of 105 control-phase
manuscripts (38%) and 27 of 68 intervention-phase
manuscripts (40%). There was no statistically significant
difference between intervention and control phases in the
primary end point (estimated difference, −6%; 90% CI, −27%
to 15%; 1-sided P = .68). Prospectively registered trials were
more likely to be published (117 of 251 trials 47%) than
unregistered trials (7 of 33 trials 21%) (model-estimated
difference, 29%; 95% CI, 10%-47%), but no significant
difference was observed between prospectively and
retrospectively registered trials (49 of 135 trials 36%
accepted; model-estimated difference, 9%; 95% CI, 1%-20%).
Conclusions The results do not support provision of a data
sheet with clinical trial registration details during peer review
to increase agreement between prospectively registered and
published trial outcomes. The high prevalence of
retrospective registration and discrepancies between
registered and published trial outcomes necessitates
identification of effective interventions for these problems.
References
1. Trinquart L, Dunn AG, Bourgeois FT. Registration of
published randomized trials: a systematic review and
meta-analysis. BMC Med. 2018;16(1):173. doi:10.1186/
s12916-018-1168-6
2. Wager E, Williams P, “Hardly worth the effort”? medical
journals’ policies and their editors’ and publishers’ views on
trial registration and publication bias: quantitative and
qualitative study. BMJ. 2013;347:f5248. doi:10.1136/bmj.
f5248
3. Ellenberg SS. The stepped-wedge clinical trial: evaluation
by rolling deployment. JAMA. 2018;319(6):607-608.
doi:10.1001/jama.2017.21993
Conflict of Interest Disclosures Christopher W. Jones
reported receiving grants from AstraZeneca, Abbott, Vapotherm,
and Ophirex outside the submitted work. Sara Schroter is a full-
time employee at The BMJ. Benyamin Margolis is an employee of
the Department of Health and Human Services in the Office of
Research Integrity. David L. Schriger is an associate editor at JAMA
and a deputy editor at Annals of Emergency Medicine. Timothy F.
Platt-Mills is an employee of Ophirex.
Funding/Support This work was supported by the US
Department of Health and Human Services Office of Research
Integrity (grant ORIIR180039).
Role of the Funder/Sponsor The sponsor had no role in
the design and conduct of the study; collection, management,
analysis, and interpretation of the data; preparation, review, or
approval of the manuscript; and decision to submit the abstract for
presentation.
Acknowledgment We thank the editors and staff members of the
following journals for their participation in this study: Academic
Emergency Medicine, American Journal of Transplantation,
Annals of Emergency Medicine, Archives of Physical Medicine
and Rehabilitation, British Journal of Ophthalmology, Clinical
Orthopaedics and Related Research, Gastroenterology, Heart,
International Journal of Cancer, Journal of the American College
of Surgeons, Neurology, Surgery, and Thorax.
Additional Information The contents of this manuscript are
those of the authors and do not represent the official views of,
nor an endorsement by, the Office of the Assistant Secretary of
Health, the Department of Health and Human Services, or the US
government. The study was registered at ISRCTN41225307.